Tag Archives: CRISPR/Cas9

Biologics Unleashed: Next-Gen Development Techniques

AoS. Biologics Unleashed: Next-Gen Development Techniques

The world of biopharmaceuticals is witnessing an era of unprecedented growth, largely fueled by the advancements in biologics development. Biologics, unlike traditional small-molecule drugs, are complex proteins derived from living cells used to treat a plethora of

Genome editing in non-dividing cells: new strategies are required

CRISPR/Cas9 system

Although rare individually, genetic disorders collectively constitute a common health problem. As the cause of these diseases is a defective gene, gene therapy would be able to resolve all of these disorders. The most recent method of

Cellular stress and AMPK activators including metformin and the anesthetic drug propofol promote restoration of human consciousness

Cellular stress and AMPK activators including Metformin

The neural mechanisms that give rise to human consciousness have been described as one of the greatest and most profound mysteries in all of modern medicine. The use of general anesthetics to induce loss of consciousness (LOC)

Emerging diversity of the CRISPR-Cas system in cholera phages

Interactions of bacteria and their phages, which are viruses hostile to bacterial survival lead to the evolution of numerous phage resistance mechanisms.  CRISPR-Cas (clustered regularly interspersed short palindromic repeats-CRISPR-associated proteins) is such a defense system of bacteria. The

Angiotensin II actions on distal regulatory elements promote vascular dysfunction and hypertension

Cardiovascular diseases such as hypertension (high blood pressure) and atherosclerosis (blocked blood vessels) lead to heart attacks and strokes, and are highly prevalent worldwide. Furthermore, these complications are significantly accelerated in patients with diabetes. Angiotensin II (AngII)

A new drug combination rescues a rare Cystic Fibrosis mutation in patient tissue

University of Toronto researchers in the laboratory of Dr. Christine Bear, together with collaborators at SickKids Hospital (Toronto, Canada) and Proteostasis Therapeutics (Cambridge, Massachusetts), used computer simulations, cell-based systems and patient tissue to interrogate the consequences of

Cyagen Biosciences – Helping you choose the right animal model for your research

While many animal models are available “ off the shelf ” through various repositories and collaborations, generation of novel animal models has allowed for more effective studies, not limited by previously derived lines/ strains. Historically, researchers have